Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

Abstract

The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses, particularly those that are stratified according to risk of serious COVID-19 outcomes. These analyses will require public release of participant level datasets.